SYDNEY, Nov. 17, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a summary of new paxalisib data ...
SYDNEY, June 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics, today announced the ...
SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and ...
SYDNEY, June 30, 2021/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two ...
Lymphoma is a cancer of white blood cells. It occurs in the lymphatic system and can spread almost anywhere in the body; primary CNS lymphoma (PCNSL) occurs exclusively in the brain and central ...
Shares of Kazia Therapeutics Ltd (NASDAQ:KZIA) are surging Wednesday following the announcement of preclinical research findings for its lead drug candidate, paxalisib. The research, conducted at the ...
SYDNEY, Jan. 30, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial ...
Kazia Therapeutics (NASDAQ:KZIA) has signed a non-binding letter of intent with an undisclosed biotech firm for the proposed granting of worldwide rights to develop and commercialize its lead ...
SYDNEY, Dec. 10, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA) today announced new data from two presentations at the 2025 San Antonio Breast Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results